Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest from Jung Won Shin
Following strong demand for offerings by D&D Pharmatech and ENCell, sentiment around biopharma IPOs in Korea appears to be improving, with several other ventures planning to float.
Plus deal news involving LianBio/NImmune, REGiMMUNE/Kiji, Chengdu Baiyu/Novartis, Orasis/Optus, Takeda/Wave Life Sciences, Ono/LigaChem, Alchem/Sonnet, Astellas/AviadoBio, Innovent/Ask Pharm and Dr Reddy’s/Gilead.
While oncology and discovery-stage assets accounted for the majority of R&D projects supported by a Korean state fund this year, new modalities such as ADCs and TPDs are emerging.
Recent major developments in the Korean biotech sector include Orum Therapeutics’ IPO plan and HLB’s US resubmission for the approval of rivoceranib in combination with camrelizumab for first-line liver cancer.
In a video interview with Scrip, Syed Husain, CEO of the US-based cell therapy CDMO BioCentriq, talks about the company’s role in parent GC’s growth strategy and business priorities, the cell and gene therapy manufacturing market and his views on the US BIOSECURE Act.
The five-year roadmap aims to expand support for AI research and development in essential health care and new drug development, as well as advance medical data usage systems and enable its safe use.